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Abstract
Background: Expert groups and national guidelines recommend individualized decision making about screening
mammography for women in their 40s at low-to-average risk of breast cancer. We created Breast Screening Decisions
(BSD), a personalized, web-based decision aid, to help women decide when to start and how often to have routine
screening mammograms. We evaluated BSD in a large, prospective pilot trial of women and their clinicians.
Methods: Women ages 40–49 were invited to use BSD before a scheduled preventive care visit. One month post-visit,
users were asked about decisional conflict, knowledge, perceptions and worry about breast cancer and screening. They
were also asked whether they had a screening mammogram since their visit, scheduled an appointment for a screening
mammogram, or if they were planning to schedule an appointment within the next six months. Women who responded
“no” to each of these successive questions were considered to have no plan for a screening mammogram within the
next 6 months, unless they explicitly stated that they were unsure about screening mammography. Clinicians were
surveyed regarding mammography discussions and perceived patient knowledge and anxiety.
Results: Of 1,100 women invited to use BSD, 253 accessed the website, and 168 were eligible to participate in the pilot
study. One-fifth had a family history of breast cancer, and at least 76% had any prior mammogram. At follow-up, 88% of
BSD users reported discussing mammography at their visit, and 77% said they had a screening mammogram since the
visit or that they made or were planning to make a screening mammogram appointment. The average decisional conflict
score was 22.5, within the threshold for implementing decisions. Decisional conflict scores were lowest in women who
said that they had or planned to have a mammogram (mean 21.4, 95% CI 18.3-24.6), higher in those who did not (mean
24.8, 95% CI 19.2-30.5), and highest in those who were unsure (mean 31.5, 95% CI 13.9-49.1). Most BSD users expressed
accurate perceptions of their breast cancer risk and the benefits and limitations of screening.
Conclusions: A web-based decision aid may support informed, individualized decisions about screening mammography
and facilitate discussions about screening between women in their 40s and their clinicians.
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Background
Screening mammography reduces breast cancer mortal-
ity by about 15% in women ages 40–49 [1], somewhat
less than the 20–30% mortality reduction in women ages
50–69. Considering the balance of benefits and harms,
in 2009 the US Preventive Services Taskforce (USPSTF)
recommended against routine screening mammograms
for women in their 40s, advising them instead to make
individual decisions about screening with their physi-
cians in the context of their personal breast cancer risk,
values and preferences [2]. The USPSTF reaffirmed this
recommendation in 2016 following an updated review of
the evidence [3]. The American Medical Association,
American College of Physicians, American Academy of
Family Physicians and the American College of Prevent-
ive Medicine supported the panel’s 2009 recommenda-
tion. The American Congress of Obstetricians and
Gynecologists (ACOG) and the American College of
Radiology expressed opposition and recommended an-
nual screening mammography starting at age 40. Until
recently, the American Cancer Society also recom-
mended annual screening for women 40 and older [4].
Controversy and conflicting guidelines have led to
confusion among women and their clinicians about
screening mammography [5–7]. We created Breast
Screening Decisions (BSD), a web-based tool to help
women in their 40s at low-to-average risk of breast can-
cer decide when to start and how often to have screen-
ing mammograms, in the context of a shared decision-
making process with their clinicians. The goal of BSD is
not necessarily to change screening behavior, but rather
to help women make decisions about screening mam-
mography that are informed and consistent with their
values and preferences [8], and to serve as a foundation
for discussions about screening mammography between
women and their health care providers. We conducted a
large pilot trial of BSD to assess its feasibility and accept-
ability in clinical practice, and to evaluate decisional
conflict, knowledge and worry about breast cancer and
screening mammography in BSD users.
Methods
Decision aid development
BSD was created using the Ottawa Decision Support
Framework [9] and evidence-based recommendations
for communication of health-related risk information
[10]. BSD content was developed with input from breast
oncologists and radiologists, internists and gynecolo-
gists. Prior to using BSD in this study, usability test-
ing was conducted with clinicians and volunteers in
the target age group, and the site was modified per
their feedback. BSD meets fully 26 of 28 International
Patient Decision Aid Standards (IPDAS) Content Cri-
teria and 17 of 20 relevant IPDAS Development
Process criteria (see Additional file 1: Table S1) [11].
Five of six criteria for internet-based decision aids
were fully met and one was partially met.
The landing page of BSD frames the two decisions the
tool is designed to address: when to start (age 40 or age
50) and how often to have (every year or every other
year) routine screening mammograms. BSD users next
complete a breast cancer risk assessment based on the
Gail model [12, 13]. In addition to eliciting the Gail
model risk factor information, BSD identifies women at
increased risk due to: 1) a first-degree relative diagnosed
with breast cancer before age 50 or ovarian cancer at
any age; 2) a prior diagnosis of ductal carcinoma in situ
or lobular carcinoma in situ; 3) a prior diagnosis of atyp-
ical ductal hyperplasia; 4) a known BRCA1/2 mutation;
or 5) a history of chest radiation. Women who report
any high-risk criteria and women with a predicted five-
year breast cancer risk ≥1.66% – consistent with ac-
cepted definitions of high risk [14] – may not proceed
with the decision aid. Instead, they are told that based
on the information they provided, they may be at
greater-than-average risk of developing breast cancer,
and that for women like them, routine mammography
and possibly other screening tests may be recommended.
They are encouraged to speak with their doctors about
their breast cancer risk and screening options.
For women who report no high-risk criteria, BSD dis-
plays their personal predicted risk of developing breast
cancer in the next 5 years. Risk information is presented
using female icon arrays, percentages and numeric fre-
quencies with explanatory text (“Of 1,000 women like
you, X will develop breast cancer in the next 5 years”).
In subsequent pages, BSD provides information about
the accuracy of screening mammograms and the benefits
and harms of routine screening. Mammogram accuracy
is expressed with icon arrays and frequencies to describe
test results and true cancer status in 1,000 women in
their 40s who have a screening mammogram, based on
published estimates from the Breast Cancer Surveillance
Consortium [1, 15].
Quantitatively, benefit is described as reduction in the
number of deaths from breast cancer associated with the
four different screening schedules reflecting different
starting ages (40 vs. 50) and screening intervals (every
year vs. every other year). This information, based on
published estimates from the Cancer Intervention and
Surveillance Modeling Network [16], is displayed using
female icon arrays and frequencies with explanatory text.
Differences in breast cancer death rates are estimated as
a function of the relative risk reduction associated with
each screening schedule and the underlying breast can-
cer mortality risk for women ages 40–49 [1].
The potential harms of routine screening described in
BSD include diagnostic work-ups associated with false-
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positive results; overdiagnosis and unnecessary treat-
ment; delayed cancer diagnosis and false reassurance as-
sociated with false-negative results; and cumulative
radiation exposure associated with repeat screening,
which is described as “extremely low.” False-positive and
false-negative rates are given quantitatively. Other harms
are described qualitatively and in plain language, with
links to additional information about these outcomes.
Following the information about benefits and harms of
screening, BSD users can explore their attitudes toward
breast cancer, screening and involvement in health care
decisions in a values-clarification exercise. Users are
asked to consider a series of 10 statements and indicate
their level of agreement or disagreement with each state-
ment. Finally, BSD provides a one-page summary of the
session, with options to save and print the summary
document, which users are encouraged to share with
their clinician.




BSD was evaluated in a prospective, single-arm trial at a
large, urban, academic medical center between March
2013 and April 2014. The study was approved by the In-
stitutional Review Board at Weill Cornell Medical
College.
We identified women ages 40–49 with a scheduled ap-
pointment for routine preventive care at one of three
participating primary care and gynecology practices.
Electronic health records (EHRs) were screened to ex-
clude women with a personal history of breast cancer
and women at increased risk of breast cancer due to one
of the five aforementioned high-risk criteria. All other
women were invited to participate and to use BSD at
their convenience before their scheduled visit. Invita-
tions, mailed and emailed 4–6 weeks before the sched-
uled visit, included a personalized letter signed by the
woman’s physician with instructions for accessing the
BSD website and a unique username and password. On-
site access to BSD at each participating clinic was of-
fered to women who did not have internet access
elsewhere.
Informed consent was obtained immediately after log-
ging into the BSD website. Women could log in more
than once and resume or repeat a session any time prior
to their scheduled visit. Women who logged in, gave
consent, met eligibility criteria and used the decision aid
(BSD users) received follow-up as described below.
There was no active follow-up with women who were
invited to use BSD but did not log in and give consent
prior to their scheduled visit (non-users), although infor-
mation in the EHR about their age and mammography
history was collected for eligibility screening and com-
parison with BSD users.
Assessments
At the conclusion of the BSD session, users completed
an online survey about their impressions of the site, with
seven statements about ease of navigation, clarity and
importance of information, usefulness of graphs and fig-
ures, time burden, and whether they would recommend
the site to other women. Responses to each statement
were given on a 5-point scale from “strongly agree” to
“strongly disagree.”
One month after each user’s scheduled preventive care
visit, she was contacted by telephone and asked to
complete a follow-up survey by phone or online. In
order to identify potential unintended impacts of the de-
cision aid on behavior, actual or intended use of screen-
ing mammography was ascertained by asking women
whether they had a screening mammogram since their
visit, scheduled an appointment for a screening mam-
mogram, or if they were planning to schedule an ap-
pointment within the next six months. Women who
responded “no” to each of these successive questions
were considered to have no plan for a screening mam-
mogram within the next 6 months, unless they explicitly
stated that they were unsure about screening mammog-
raphy in response to the final question. Decisional con-
flict was assessed using O'Connor’s Decisional Conflict
Scale (DCS), a 16-item instrument developed to evaluate
health care decision support interventions [17]. The
DCS has high reliability, and DCS scores below 25 have
been associated with implementing decisions. Breast
cancer worry was assessed using items adapted from
McCaul’s Breast Cancer Worry Scale (BCWS) [18]. Sub-
jects were asked how often they worry about breast can-
cer, how often worry about breast cancer affects their
mood, and how often worry about breast cancer affects
their performance of daily activities, with responses
given on a 5-point scale from “not at all” to “almost all
the time”. Knowledge and beliefs about breast cancer
and screening mammography were assessed using indi-
vidual items developed for this study or selected from
existing instruments [19]. Information about each sub-
ject’s age, race, marital status, number of children, type
of health insurance and prior use of mammography –
for screening or diagnostic purposes – was obtained
from the EHR.
Clinicians were asked to complete a brief paper survey
at the conclusion of each woman’s scheduled preventive
care visit. They were asked if screening mammography
was discussed during the visit, the duration of the dis-
cussion in minutes, whether the patient seemed in-
formed about screening mammography and whether the
patient seemed anxious about mammography or breast
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cancer. Responses to these questions were given on a 5-
point scale. Clinicians were blinded to information about
each woman’s use of the decision aid, unless a woman
volunteered this information during her scheduled visit.
Thus, clinician assessments were conducted for both
BSD users and non-users.
Analysis
All survey responses were analyzed using descriptive sta-
tistics, including frequencies, means and medians. DCS
scores were estimated using that instrument’s scoring al-
gorithm. Associations between predicted breast cancer
risk and responses to selected items in the follow-up
survey were assessed using one-way analysis of variance
(ANOVA). Analysis of associations between between
other outcomes were assessed using Fisher’s exact test.
All analyses were performed in SAS (version 9.4, Cary,
NC).
Results
Characteristics of the Sample
From March 1, 2013 through June 30, 2014, invitations
were mailed to 1,100 women ages 40–49 with a sched-
uled preventive care visit who had no study exclusion
criteria identified in the EHR. Of these women, 253
logged in to the BSD website and 194 provided consent,
of whom 168 met criteria for low-to-average breast can-
cer risk (Fig. 1). BSD users and non-users had the same
median age (44 years). Among women with information
available in the EHR, the probability of any prior mam-
mogram (screening or diagnostic) was similar in BSD
users (76%) and non-users (84%).
BSD users were predominantly white, most were mar-
ried, had at least one child, and were non-smokers
(Table 1). Nearly all had private, commercial health in-
surance. At least 24% of BSD users had any family his-
tory of breast cancer in someone other than a first-
degree relative diagnosed at age 50 or younger, and at
least 74% had a prior screening mammogram. Based on
the information entered in the decision aid by users,
predicted 5-year breast cancer risk varied from 0.4% to
1.6%, with a median of 1.0%. Median lifetime breast can-
cer risk was 12.5%.
Impressions of the site
At least 97 of the 168 eligible users (58%) completed the
exit survey on the final page of BSD, and therefore
viewed all prior pages. A majority of these women
expressed favorable impressions of BSD. More than 95%
agreed or strongly agreed that the site was easy to navi-
gate, that the information was presented clearly, and that
the information was important for women like them.
Seventy-six percent said that graphs and illustrations
helped them understand the information presented. No
users said that information in BSD was confusing, and
only 5% reported that the website was too slow. Almost
80% said they would recommend BSD to other women
in their 40s.
Screening decisions and decisional conflict
Of the 168 eligible women who gave consent and used
BSD, 120 responded to at least one item in the follow-up
survey. Of these women, 88% reported that they discussed
screening mammography at their scheduled visit, and 77%
said they had a screening mammogram since the visit, had
scheduled an appointment for a screening mammogram,
or were planning to make an appointment in the next
6 months (Fig. 2). The average decisional conflict score
was 22.5, below the threshold score of 25 associated with
implementing decisions [17, 20]. Decisional conflict scores
were lowest among women who reported that they had or
planned to have a mammogram (mean 21.4, 95% CI 18.3-
24.6) higher in those who did not (mean 24.8, 95% CI
19.2-30.5), and highest in those who were unsure (mean
31.5, 95% CI 13.9-49.1) (Table 2).
Knowledge and worry about breast cancer and screening
BSD users generally expressed accurate perceptions of
their own breast cancer risk and the benefits and limita-
tions of screening (Table 3). However, 10% believed that
they were more likely to get breast cancer than the aver-
age woman their age. Eighty-three percent agreed or
strongly agreed that, for them, the benefits of screening
outweighed the potential risks. Women who expressed
this belief were considerably more likely than those who
disagreed to report that they had a screening
Fig. 1 Study recruitment
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mammogram, had an appointment for screening or
planned to make an appointment within the next
6 months (84% vs. 25%). Women with no plan for a
screening mammogram were more likely to disagree or
strongly disagree with the statement that the benefits of
screening outweighed the risks, compared with BSD
users who had or planned to have a mammogram (20%
vs. 2%, p < 0.01 by Fisher’s exact test). Nearly all BSD
users (96%) said that their doctor was knowledgeable
about the benefits and risks of screening mammography.
When asked how often they worry about breast cancer,
more than one-fifth of BSD users said not at all, while
only one user said almost all of the time. When asked
how often breast cancer worry affected their mood and
how often it affected their performance of daily activ-
ities, 69% and 86% of users, respectively, said not at all.
However, 70% agreed or strongly agreed that having a
screening mammogram would help them worry less
about breast cancer.
Role of predicted risk
There was no association between a user’s predicted
breast cancer risk, based on the Gail model and given to
her in BSD, and actual or intended use of screening.
However, risk perception and worry about breast cancer
varied with predicted risk. Women with higher predicted
risk were more like to agree with the statement, “I am
more likely to get breast cancer than the average woman
my age,” while those with lower predicted risk were
more likely to (correctly) disagree with this statement (p
< 0.01 by ANOVA). Women with higher predicted risk
were also more likely to report more frequent worry
about breast cancer (p < 0.01 by ANOVA).
Clinician perceptions
Clinician surveys were available for 110 of the 168 BSD
users (65%) and for 618 non-users who met study eligi-
bility criteria based on information found in the EHR.
For 87% of BSD users and 84% of non-users, clinicians
reported that the patient seemed well-informed about
screening mammography. For 88% of BSD users and
94% of non-users, clinicians disagreed or expressed neu-
trality with the statement that the patient seemed anx-
ious about screening mammography. Rates of clinician-
reported mammography discussion were similar in users
and non-users (90% and 92%), and for both groups the
average time that clinicians reported discussing mam-
mography was four minutes. Differences between users
and non-users for these clinician-reported endpoints
were not statistically significant.
Discussion
Users of our personalized, web-based decision aid re-
ported low levels of decisional conflict and high levels of


















Never smoker 134 80
Current smoker 1 <1





Family history of breast cancer*
Yes 40 24












No information 11 7
All information obtained from electronic health records, except for race/
ethnicity, which was reported by users in the breast cancer risk assessment
portion of the decision aid
*Women with a family history of breast cancer in a 1st-degree relative before
age 50 were excluded
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knowledge about breast cancer risk and screening. Most
discussed breast cancer screening with a physician, and
their clinicians perceived them to be well informed
about screening mammography.
Many women overestimate the benefits of mammog-
raphy, some even holding the mistaken belief that
screening can prevent breast cancer [21]. Most BSD
users in our study (79%) agreed that having a screening
mammogram would reduce their chance of dying from
breast cancer, a fact stated in the decision aid. Contrary
to information presented in BSD, 8% of users said that
screening mammography can detect all breast cancers. It
is not clear whether these women were unable to
process or retain information presented in the decision
aid, or whether their beliefs about screening mammog-
raphy were too strong to counteract conflicting
information.
BSD was designed for women at low-to-average risk of
developing breast cancer, and eligible users are told that
they are at low-to-average risk based on their personal-
ized risk prediction. Despite this, 10% of BSD users per-
ceived that they were “more likely to get breast cancer
than the average woman” their age. Thus, for some
women there is discordance between perception and in-
formation, even when breast cancer risk estimates are
personalized and stated explicitly, perhaps due to lack of
confidence in those estimates [22].
In the context of disease screening, decision aids have
been shown to improve knowledge, reduce decisional
conflict and anxiety, allow patients to be active partici-
pants in their care and lead to informed, values-based
decisions [23–25]. A screening mammography decision
aid for Australian women under 50 increased knowledge
and reduced indecision without increasing feelings of
anxiety [26], and information about “overdetection” of
breast cancer further enhanced the likelihood of making
an informed decision [27].
In the absence of a comparison or control group in
our study, we cannot make causal inferences about BSD
and its relationship with decision-making outcomes.
BSD users were a self-selected group, and their prior
knowledge, attitudes and beliefs about screening may
have differed from those of non-users. However, the high
levels of knowledge we observed, and relatively low
levels of decisional conflict and worry, suggest that BSD
did not have a detrimental impact on these important
outcomes. Similarly, we did not find a large difference
between the proportion of users with evidence of prior
screening (74%), and the proportion of users who re-
ported actual or intended use of screening mammog-
raphy following their post-BSD preventive care visit
(77%), suggesting that BSD was not biased for or against
any particular screening strategy and did not cause dra-
matic changes in behavior. BSD did not appear to influ-
ence clinician perceptions of patient knowledge, but
perhaps more importantly, it did not significantly in-
crease clinician-perceived patient anxiety about screen-
ing or the length of discussions about screening. These
results suggest that BSD did not add a burden to the
clinical encounter or adversely affect the clinician-
patient interaction from the provider perspective.
Our study included women of different racial and eth-
nic backgrounds, who also likely varied in their socio-
economic status. However, 80% of the sample was white,
77% were married, and 96% had commercial health in-
surance, and our findings may not be generalizable to
Fig. 2 Actual and intended use of screening in BSD users*. *Self-reported in follow-up survey one month after scheduled preventive care visit
following use of Breast Screening Decisions (BSD)
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different populations, particularly those with a greater
proportion of African-American women or a greater
proportion of uninsured women. Similarly, the numer-
acy, health literacy and internet comfort of our sample
may not be generalizable to all US women in their 40s.
Socially disadvantaged groups, including those with lim-
ited education or low literacy, may benefit from decision
aids specifically tailored to their needs [28].
BSD itself has several limitations, some due to limita-
tions of available evidence. For example, breast cancer
risk estimates were personalized, but estimates of
screening benefit were age group-specific. Other limita-
tions reflect deliberate decisions to maximize user com-
prehension and reduce confusion. For example, breast
cancer risk and screening benefit are presented as point
estimates without ranges or confidence intervals. Effect-
ively communicating uncertainty with lay audiences is
challenging, and there is currently no consensus on best
practices [29]. Although we reviewed many decision aids
for cancer screening as we developed BSD, we cannot
say whether BSD is superior to other web-based decision
aids for breast cancer screening or even if a web-based
tool is appropriate for all women in their 40s at low-to-
average risk of breast cancer.
There are approximately 22 million women ages 40–
49 in the US, each of whom is advised, by the USPSTF
and others, to make an individualized decision regarding
screening mammography in consultation with her phys-
ician. While some expert groups continue to recom-
mend that women ages 40–49 be offered annual
mammography, not all women accept this offer. Use of a
decision aid could alleviate medico-legal concerns that
some clinicians have in supporting their patients’ indi-
vidualized screening mammography decisions, especially
amid conflicting and often sensationalized reports in the
popular press [30]. Even ACOG, which recommends an-
nual screening mammograms, recently advised that deci-
sions about screening start age and frequency “should be
made through shared decision making,” and that “health
care providers should work with patients to determine
the best screening strategy based on individual risk and
values” [31]. BSD directly addresses this recommenda-
tion, offering women personalized estimates of their
breast cancer risk and an opportunity to explore their
values and preferences. BSD also provides balanced,
evidence-based information about screening options,
consistent with recent calls for patient-centered, in-
formed consent that meets a “reasonable patient” stand-
ard and advances shared decision making [32].








I am more likely to get breast cancer than the average woman my age 10 20 70
My chance of developing breast cancer in the next 10 years is fairly low 70 27 3
My chance of developing breast cancer will increase as I get older 61 30 9
Screening mammography can detect all breast cancers 8 16 76
If a screening mammogram identifies an abnormality, it is definitely breast
cancer
0 3 97
All abnormalities identified in a screening mammogram need to be
removed
1 5 94
Having a screening mammogram will reduce my chance of dying from
breast cancer
79 13 8
Having a screening mammogram will be inconvenient 38 16 46
Having a screening mammogram will be painful 35 24 41
Having a screening mammogram will help me worry less about breast
cancer
70 16 14
For me, the potential benefits of a screening mammogram outweigh the
potential risks
83 10 7
My doctor is knowledgeable about the benefits and risks of screening
mammography
96 3 1
Table 2 Decisional conflict and use of screening
Actual or Intended Use of Screening Mammography*
Yes No Unsure
n = 89 n = 20 n = 6
DCS score 21.4 24.8 31.5
95% CI 18.3–24.6 19.2–30.5 13.9–49.1
*Yes: respondent reported having mammogram since post-decision aid visit,
having appointment for mammogram, or planning to schedule appointment
within six months
DCS Decisional conflict scale
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Conclusions
In a large pilot study, users of Breast Screening Deci-
sions, a web-based decision aid, reported high levels of
knowledge about breast cancer risk and screening and
low levels of decisional conflict and worry. Most users
subsequently discussed breast cancer screening with a
clinician, and BSD did not appear to adversely affect the
patient-clinician interaction from the clinician’s perspec-
tive. Our results suggest that decision aids like BSD may
help women in their 40s make informed, personalized
decisions about screening mammography.
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